TSH Biopharm Corporation Limited (TPEX:8432)
51.00
-1.10 (-2.11%)
Mar 9, 2026, 1:30 PM CST
TSH Biopharm Corporation Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 139.26 | 113.09 | 61.99 | 61.89 | 47.11 | Upgrade
|
| Depreciation & Amortization | 26.74 | 27.56 | 21.34 | 20.61 | 9.65 | Upgrade
|
| Other Amortization | - | 1.4 | 1.23 | 0.91 | 0.14 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0.87 | 0.04 | 0.06 | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 8.8 | - | - | 4.15 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.11 | - | - | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.9 | 0.76 | -1.93 | 3.04 | -0.1 | Upgrade
|
| Other Operating Activities | 37.64 | 35.14 | -8.83 | -1.3 | -15.64 | Upgrade
|
| Change in Accounts Receivable | -99.41 | 48.61 | -5.52 | -10.41 | 9.05 | Upgrade
|
| Change in Inventory | 20.33 | -44.91 | -11.01 | -13.95 | 4.69 | Upgrade
|
| Change in Accounts Payable | -22.73 | -43.14 | -5.93 | -49.46 | 6.33 | Upgrade
|
| Change in Unearned Revenue | 2.21 | -0.8 | -3.59 | 5.23 | - | Upgrade
|
| Change in Other Net Operating Assets | 35.69 | 36.4 | -13.93 | 17.74 | 3.34 | Upgrade
|
| Operating Cash Flow | 139.52 | 183.77 | 33.87 | 34.35 | 68.71 | Upgrade
|
| Operating Cash Flow Growth | -24.08% | 442.54% | -1.40% | -50.00% | 491.74% | Upgrade
|
| Capital Expenditures | -4.52 | -1.73 | -5.38 | -3.73 | -0.38 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.3 | - | 0.03 | - | Upgrade
|
| Cash Acquisitions | - | -242.87 | - | - | - | Upgrade
|
| Divestitures | 1.47 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -5.88 | -1.02 | -0.18 | -15 | - | Upgrade
|
| Investment in Securities | -158.95 | 127.94 | 167.87 | 44.67 | -14.28 | Upgrade
|
| Other Investing Activities | 3.07 | 6.99 | -1.29 | 7.42 | 4.6 | Upgrade
|
| Investing Cash Flow | -164.82 | -110.38 | 161.02 | 33.4 | -10.06 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 20 | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 30 | - | Upgrade
|
| Total Debt Issued | - | - | - | 50 | - | Upgrade
|
| Short-Term Debt Repaid | - | - | -20 | -61.07 | - | Upgrade
|
| Long-Term Debt Repaid | -12.24 | -12.54 | -35.73 | -20.93 | -4.35 | Upgrade
|
| Total Debt Repaid | -12.24 | -12.54 | -55.73 | -82 | -4.35 | Upgrade
|
| Net Debt Issued (Repaid) | -12.24 | -12.54 | -55.73 | -32 | -4.35 | Upgrade
|
| Common Dividends Paid | -81.4 | -49.15 | -61.44 | -57.6 | -69.12 | Upgrade
|
| Other Financing Activities | -4.86 | - | 9.99 | 0.2 | - | Upgrade
|
| Financing Cash Flow | -98.51 | -61.69 | -107.18 | -89.4 | -73.46 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 0.06 | -0.03 | 0.03 | - | Upgrade
|
| Net Cash Flow | -123.8 | 11.76 | 87.68 | -21.62 | -14.81 | Upgrade
|
| Free Cash Flow | 135 | 182.04 | 28.49 | 30.62 | 68.33 | Upgrade
|
| Free Cash Flow Growth | -25.84% | 538.93% | -6.96% | -55.18% | 604.75% | Upgrade
|
| Free Cash Flow Margin | 10.10% | 16.32% | 3.51% | 4.13% | 16.52% | Upgrade
|
| Free Cash Flow Per Share | 3.51 | 4.74 | 0.74 | 0.80 | 1.78 | Upgrade
|
| Cash Interest Paid | - | 0.46 | 0.69 | 0.7 | 0.08 | Upgrade
|
| Cash Income Tax Paid | - | 19.24 | 15.9 | 13.98 | 23.74 | Upgrade
|
| Levered Free Cash Flow | -351.72 | 138.94 | 8.75 | -18.85 | 62.7 | Upgrade
|
| Unlevered Free Cash Flow | -351.23 | 139.23 | 9.18 | -18.41 | 62.75 | Upgrade
|
| Change in Working Capital | -63.9 | -3.84 | -39.97 | -50.86 | 23.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.